Molecular profiling of childhood cancer: Biomarkers and novel therapies

BBA Clinical

Volumn 1, Issue , 2014, Pages 59-77

  Saletta, Federica ^a   Wadham, Carol ^b   Ziegler, David S ^b,c   Marshall, Glenn M ^b,c   Haber, Michelle ^b   McCowage, Geoffrey ^a   Norris, Murray D ^b   Byrne, Jennifer A ^a,d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of New South Wales Sydney   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biomarkers; Childhood cancer; Molecular diagnostics; Targeted therapy

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL] UREA; 1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; BLINATUMOMAB; BORTEZOMIB; CD19 ANTIBODY; CEDIRANIB; CERITINIB; CLOFARABINE; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FENRETINIDE; FOSTAMATINIB; GEMTUZUMAB OZOGAMICIN; IRINOTECAN; MIDOSTAURIN; MYC PROTEIN; PERIFOSINE; PERTUZUMAB; PILARALISIB; QUIZARTINIB; SELUMETINIB; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL) MORPHOLINIO] METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

AUTOIMMUNE THROMBOCYTOPENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; EVENT FREE SURVIVAL; EWING SARCOMA; GENE MUTATION; HUMAN; IC 50; IMMUNOTHERAPY; JUVENILE MYELOMONOCYTIC LEUKEMIA; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; NEUROECTODERM TUMOR; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; RHEUMATOID ARTHRITIS; SOLID TUMOR; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TREATMENT OUTCOME; UPREGULATION; UTERINE CERVIX CANCER; WNT SIGNALING PATHWAY;

EID: 84904875806     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2014.06.003     Document Type: Review

References (329)

1. American Cancer Society Cancer Facts & Figs. 2014 2014, American Cancer Society, Atlanta, Ga.
2. Siegel R., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62(4):220-241.
3. Sardi I., Cavalieri D., Massimino M. Emerging treatments and gene expression profiling in high-risk medulloblastoma. Paediatr. Drugs 2007, 9(2):81-96.
4. Owens C., Irwin M. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. Crit. Rev. Clin. Lab. Sci. 2012, 49(3):85-115.
5. Loh M.L., Mullighan C.G. Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. Clin. Cancer Res. 2012, 18(10):2754-2767.
6. Bernstein M.L. Targeted therapy in pediatric and adolescent oncology. Cancer 2011, 117(10 Suppl.):2268-2274.
7. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000, 182(3):311-322.
8. Westermark U.K., et al. The MYCN oncogene and differentiation in neuroblastoma. Semin. Cancer Biol. 2011, 21(4):256-266.
9. Henze G., et al. Serum S100-a marker for disease monitoring in metastatic melanoma. Dermatology 1997, 194(3):208-212.
10. Stegmeier F., et al. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 2010, 87(5):543-552.
11. Schultz K.R., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J. Clin. Oncol. 2009, 27(31):5175-5181.
12. La Madrid A.M., et al. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target. Oncol. 2012, 7(3):199-210.
13. Ou S.H. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des. Dev. Ther. 2011, 5:471-485.
14. Shannon K. Genetic predispositions and childhood cancer. Environ. Health Perspect. 1998, 106(Suppl. 3):801-806.
15. Patel J.N., Mandock K., McLeod H.L. Clinically relevant cancer biomarkers and pharmacogenetic assays. J. Oncol. Pharm. Pract. 2014, 20:65-72.
16. Belson M., Kingsley B., Holmes A. Risk factors for acute leukemia in children: a review. Environ. Health Perspect. 2007, 115(1):138-145.
17. Smith M.T., et al. Molecular biomarkers for the study of childhood leukemia. Toxicol. Appl. Pharmacol. 2005, 206(2):237-245.
18. Chang B.H., et al. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br. J. Haematol. 2012, 157(4):507-510.
19. Gnoni A., et al. Dasatinib: an anti-tumour agent via Src inhibition. Curr. Drug Targets 2011, 12(4):563-578.
20. Aplenc R., et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J. Clin. Oncol. 2011, 29(7):839-844.
21. Keating G.M., Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009, 69(2):223-240.
22. Widemann B.C., et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin. Cancer Res. 2012, 18(21):6011-6022.
23. Goemans B.F., et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leuk. Res. 2010, 34(10):1302-1307.
24. Deisseroth A., et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin. Cancer Res. 2012, 18(12):3212-3217.
25. Maude S.L., et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120(17):3510-3518.
26. Perova T., et al. AACR 103rd Annual Meeting, Abstract 867: Therapeutic potential of small molecule SYK inhibitors for treatment of primary B cell acute lymphoblastic leukemia. Cancer Res. 2012, 72(8, Supp 1).
27. Uckun F.M., et al. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood 2013, 121(21):4348-4354.
28. Uckun F., et al. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. Arzneimittelforschung 2011, 61(4):252-259.
29. Macy M.E., et al. Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr. Oncol. Rep. 2008, 10(6):477-490.
30. Widemann B.C., et al. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2011, 56(2):226-233.
31. Goodwin C.B., et al. Genetic disruption of the PI3K regulatory subunits, p85 alpha, p55 alpha, and p50 alpha, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. Haematologica 2012, 97(7):1042-1047.
32. Reynolds C.P., et al. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr. Blood Cancer 2013, 60(5):791-798.
33. Podesta J.E., et al. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leuk. Res. 2011, 35(9):1273-1275.
34. Jayanthan A., et al. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells. Leuk. Lymphoma 2013, 54(7):1505-1516.
35. Maris J.M., et al. Initial testing of the aurora Kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 2010, 55(1):26-34.
36. Carol H., et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother. Pharmacol. 2011, 68(5):1291-1304.
37. Keshelava N., et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr. Blood Cancer 2009, 53(3):505-508.
38. Fouladi M., et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J. Clin. Oncol. 2010, 28(22):3623-3629.
39. Hawkins L.M., Jayanthan A.A., Narendran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr. Res. 2005, 57(3):430-437.
40. Lock R.B., et al. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr. Blood Cancer 2013, 60(7):E42-E45.
41. Garst J. Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert Opin. Drug Saf. 2007, 6(1):53-62.
42. Hijiya N., et al. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 2008, 112(9):1983-1991.
43. Inaba H., et al. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer 2010, 116(1):98-105.
44. Varadhachary G.R., Hoff P.M. Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. Semin. Oncol. 2005, 32(6 Suppl. 9):S40-S42.
45. Goto H., et al. Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children. Leuk. Res. 2009, 33(10):1386-1391.
46. Hijiya N., et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009, 23(12):2259-2264.
47. Hijiya N., et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011, 118(23):6043-6049.
48. Houghton P.J., et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50(1):37-45.
49. Horton T.M., et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin. Cancer Res. 2007, 13(5):1516-1522.
50. Horton T.M., et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 2006, 58(1):13-23.
51. Messinger Y., et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr. Blood Cancer 2010, 55(2):254-259.
52. Messinger Y.H., et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood 2012, 120(2):285-290.
53. Vedi, A., and D.S. Ziegler, Antibody therapy for pediatric leukemia. Front Oncol, 4: 82.
54. Meinhardt A., et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J. Clin. Oncol. 2010, 28(19):3115-3121.
55. Griffin T.C., et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2009, 52(2):177-181.
56. Angiolillo A.L., et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr. Blood Cancer 2009, 53(6):978-983.
57. Law J., et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol. Blood. Marrow. Transplant. 2012, 18(11):1656-1663.
58. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12(4):278-287.
59. FitzGerald D.J., et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 2011, 71(20):6300-6309.
60. Sharkey R.M., Goldenberg D.M. Cancer radioimmunotherapy. Immunotherapy 2011, 3(3):349-370.
61. Arceci R.J., et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005, 106(4):1183-1188.
62. Aplenc R., et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J. Clin. Oncol. 2008, 26(14):2390-3295.
63. Wayne A.S., et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood 2011, 118. Abstract 248, (ASH Annual Meeting Abstracts).
64. Rytting M., et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphocytic leukaemia. Pediatr. Blood Cancer 2014, 61(2):369-372.
65. Carol H., et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin. Cancer Res. 2013, 19(7):1795-1805.
66. Hoffman L.M., Gore L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front. Oncol. 2014, 4:63.
67. Handgretinger R., et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011, 25(1):181-184.
68. von Stackelberg A., et al. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood 2013, 122(21):70.
69. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U. S. A. 1989, 86(24):10024-10028.
70. Lee D.W., et al. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin. Cancer Res. 2012, 18(10):2780-2790.
71. Till B.G., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112(6):2261-2271.
72. Curran K.J., et al. ASH Annual Meeting, Abstracts 120: CD19 targeted allogeneic EBV-specific T cells for the treatment of relapsed ALL in pediatric patients post HSCT. Blood 2012, 120. Abstract 353, (ASH Annual Meeting Abstracts).
73. Grupp S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368(16):1509-1518.
74. Napper, A.D. and Watson V.G., Targeted drug discovery for pediatric leukemia. Front Oncol, 3: 170.
75. Park J.R., et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr. Blood Cancer 2013, 60(6):985-993.
76. Zirath H., et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(25):10258-10263.
77. Mertz J.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(40):16669-16674.
78. Mujtaba S., Zeng L., Zhou M.M. Structure and acetyl-lysine recognition of the bromodomain. Oncogene 2007, 26(37):5521-5527.
79. Zuber J., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478(7370):524-528.
80. Puissant A., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3(3):308-323.
81. Dominguez-Sola D., et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007, 448(7152):445-451.
82. Cole K.A., et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(8):3336-3341.
83. Walton M.I., et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin. Cancer Res. 2012, 18(20):5650-5661.
84. Reynolds C.P., et al. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003, 197(1-2):185-192.
85. Maurer B.J., et al. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst. 1999, 91(13):1138-1146.
86. Garaventa A., et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 2003, 9(6):2032-2039.
87. Villablanca J.G., et al. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin. Cancer Res. 2011, 17(21):6858-6866.
88. Di Paolo D., et al. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. J. Control. Release 2013, 170(3):445-451.
89. Parsons K., et al. Targeted immunotherapy for high-risk neuroblastoma-the role of monoclonal antibodies. Ann. Pharmacother. 2013, 47(2):210-218.
90. Yu A.L., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 2010, 363(14):1324-1334.
91. Navid F., et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J. Clin. Oncol. 2014, 32(14):1445-1452.
92. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr. Cancer Drug Targets 2009, 9(6):729-737.
93. Izycka-Swieszewska E., et al. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol. J. Pathol. 2010, 61(4):192-198.
94. Li Z., et al. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J. Natl. Cancer Inst. 2010, 102(11):758-770.
95. Li Z., et al. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer 2011, 117(23):5412-5422.
96. Kushner B.H., et al. ANR 2012, Abstract POC27: Targeting the PI3K/Akt Pathway: Perifosine Monotherapy for Resistant Neuroblastoma (NB) in a Phase I/Ib Study 2012.
97. Karar J., Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 2011, 4:51.
98. Spunt S.L., et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J. Clin. Oncol. 2011, 29(21):2933-2940.
99. Geoerger B., et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 2012, 48(2):253-262.
100. Peirce S.K., et al. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother. Pharmacol. 2011, 68(2):325-335.
101. Opel D., et al. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin. Cancer Res. 2011, 17(10):3233-3247.
102. Segerström L., et al. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int. J. Cancer 2011, 129(12):2958-2965.
103. Chanthery Y.H., et al. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci. Transl. Med. 2012, 4(115). (115ra3).
104. Seitz C., et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int. J. Cancer 2013, 132(11):2682-2693.
105. Mosse Y.P., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455(7215):930-935.
106. Azarova A.M., Gautam G., George R.E. Emerging importance of ALK in neuroblastoma. Semin. Cancer Biol. 2011, 21(4):267-275.
107. Passoni L., et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009, 69(18):7338-7346.
108. Mosse Y.P., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013, 14(6):472-480.
109. Mehra R., et al. ASCO Annual Meeting, Abstract 3007: First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumours. J. Clin. Oncol. 2012, 30(15 Suppl.).
110. Jakacki R.I., et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J. Clin. Oncol. 2008, 26(30):4921-4927.
111. Donfrancesco A., et al. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Pediatr. Blood Cancer 2010, 54(1):55-61.
112. Furman W.L., et al. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest. New Drugs 2012, 30(4):1660-1670.
113. Richards K.N., et al. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 2010, 116(13):3233-3243.
114. Minturn J.E., et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother. Pharmacol. 2011, 68(4):1057-1065.
115. Iyer R., et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin. Cancer Res. 2010, 16(5):1478-1485.
116. Iyer R., et al. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemother. Pharmacol. 2012, 70(3):477-486.
117. Zage P.E., et al. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer 2011, 117(6):1321-1391.
118. Zage P.E., et al. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer 2010, 116(10):2465-2475.
119. Beaudry P., et al. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol. Cancer Ther. 2008, 7(2):418-424.
120. Maris J.M., et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50(3):581-587.
121. Morton C.L., et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr. Blood Cancer 2012, 58(4):566-571.
122. Grinshtein N., et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res. 2011, 71(4):1385-1395.
123. Spaniol K., Boos J., Lanvers-Kaminsky C. An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Anticancer Drugs 2011, 22(6):531-542.
124. Timeus F., et al. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol. Rep. 2008, 19(2):353-359.
125. Vitali R., et al. Activity of tyrosine kinase inhibitor dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int. J. Cancer 2009, 125(11):2547-2555.
126. Keisner S.V., Shah S.R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71(4):443-454.
127. Kumar S., et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 2011, 17(17):5656-5667.
128. Kakodkar N.C., et al. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr. Blood Cancer 2012, 59(4):642-647.
129. Rock E.P., et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12(1):107-113.
130. Zhang L., et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009, 11(5):426-435.
131. Ioannidis S., et al. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyraz ol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J. Med. Chem. 2011, 54(1):262-276.
132. Yan S., Li Z., Thiele C.J. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in neuroblastoma and pediatric sarcomas in vitro and in vivo. Oncotarget 2013, 4(3):433-445.
133. Mosse Y.P., et al. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin. Cancer Res. 2012, 18(21):6058-6064.
134. Muscal J.A., et al. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest. New Drugs 2013, 31(1):39-45.
135. Muscal J.A., et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr. Blood Cancer 2013, 60(3):390-395.
136. Panicker J., et al. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell Cycle 2010, 9(9):1830-1838.
137. Jaboin J., et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002, 62(21):6108-6115.
138. Wagner L.M., et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J. Clin. Oncol. 2009, 27(8):1290-1296.
139. Bagatell R., et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J. Clin. Oncol. 2011, 29(2):208-213.
140. Kushner B.H., et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J. Clin. Oncol. 2006, 24(33):5271-5276.
141. Tsang P.S., et al. Synthetic lethal screen identifies NF-kappaB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC Cancer 2012, 12:101.
142. Sottile F., et al. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget 2012, 3(5):535-545.
143. Simon T., et al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J. Pediatr. Hematol. Oncol. 2007, 29(2):101-106.
144. Simon T., et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J. Cancer Res. Clin. Oncol. 2007, 133(9):653-661.
145. London W.B., et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J. Clin. Oncol. 2010, 28(24):3808-3815.
146. Kushner B.H., et al. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer 2013, 119(3):665-671.
147. Meco D., et al. Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models. Cancer Chemother. Pharmacol. 2012, 70(6):811-822.
148. Zucchetti M., et al. Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts. Cancer Chemother. Pharmacol. 2010, 66(4):635-641.
149. Di Francesco A.M., et al. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochem. Pharmacol. 2005, 70(8):1125-1136.
150. Pastorino F., et al. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin. Cancer Res. 2010, 16(19):4809-4821.
151. Kakodkar N.C., et al. The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatr. Blood Cancer 2011, 56(1):164-167.
152. Gamble L.D., et al. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Front. Oncol. 2012, 2:162.
153. Hogarty M.D., et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008, 68(23):9735-9745.
154. Bagatell R., et al. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int. J. Cancer 2005, 113(2):179-188.
155. Chinn D.C., et al. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr. Blood Cancer 2012, 58(6):885-890.
156. Castel V., Segura V., Berlanga P. Emerging drugs for neuroblastoma. Expert Opin. Emerg. Drugs 2013, 18(2):155-171.
157. Fleming A.J., Chi S.N. Brain tumors in children. Curr. Probl. Pediatr. Adolesc. Health Care 2012, 42(4):80-103.
158. Heath J.A., Zacharoulis S., Kieran M.W. Pediatric neuro-oncology: current status and future directions. Asia Pac. J. Clin. Oncol. 2012, 8(3):223-231.
159. Mutter N., Stupp R. Temozolomide: a milestone in neuro-oncology and beyond?. Expert. Rev. Anticancer. Ther. 2006, 6(8):1187-1204.
160. Hegi M.E., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352(10):997-1003.
161. Stupp R., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002, 20(5):1375-1382.
162. Gururangan S., et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007, 9(2):161-168.
163. Cohen K.J., et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011, 13(4):410-416.
164. Broniscer A., et al. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin. Cancer Res. 2007, 13(22 Pt 1):6712-6718.
165. Warren K.E., et al. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J. Neurooncol. 2012, 106(3):643-649.
166. Adair J.E., et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci. Transl. Med. 2012, 4(133):133ra57.
167. Daniel R.A., et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br. J. Cancer 2010, 103(10):1588-1596.
168. van Vuurden D.G., et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011, 2(12):984-996.
169. Northcott P.A., et al. Molecular subgroups of medulloblastoma. Expert. Rev. Neurother. 2012, 12(7):871-884.
170. Buonamici S., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2(51):51ra70.
171. Romer J.T., et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004, 6(3):229-240.
172. Sasai K., et al. Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res. 2007, 67(8):3871-3877.
173. De Smaele E., Ferretti E., Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr. Opin. Investig. Drugs 2010, 11(6):707-718.
174. Wong H., et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin. Cancer Res. 2011, 17(14):4682-4692.
175. Rudin C.M., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 2009, 361(12):1173-1178.
176. Ferruzzi P., et al. In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines. Int. J. Cancer 2012, 131(2):E33-E44.
177. Rohner A., et al. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Mol. Cancer Ther. 2012, 11(1):57-65.
178. Yalon M., et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr. Blood Cancer 2013, 60(1):71-76.
179. Krueger D.A., et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 2013, 80(6):574-580.
180. Becher O.J., et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 2010, 70(6):2548-2557.
181. Dougherty M.J., et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 2010, 12(7):621-630.
182. Kolb E.A., et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2010, 55(4):668-677.
183. Widemann B.C., et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J. Clin. Oncol. 2006, 24(3):507-516.
184. Haas-Kogan D.A., et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011, 13(3):298-306.
185. Trippett T.M., et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J. Clin. Oncol. 2009, 27(30):5102-5108.
186. Rajappa P., et al. Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. Interv. Neuroradiol. 2011, 17(4):459-465.
187. Cabanas R., et al. Treatment of children with high grade glioma with nimotuzumab: a 5-y institutional experience. MAbs 2013, 5(2):202-207.
188. Vera D.R., et al. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl. Med. Biol. 2012, 39(1):3-13.
189. Vredenburgh J.J., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13(4):1253-1259.
190. Narayana A., et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010, 12(9):985-990.
191. Gururangan S., et al. Lack of efficacy of bevacizumab+irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2012, 14(11):1404-1412.
192. Packer R.J., et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr. Blood Cancer 2009, 52(7):791-795.
193. Broniscer A., et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin. Cancer Res. 2009, 15(2):701-707.
194. Geoerger B., et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011, 13(1):109-118.
195. Meco D., et al. Antitumor effect in medulloblastoma cells by gefitinib: ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro Oncol. 2009, 11(3):250-259.
196. Freeman B.B., et al. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest. 2006, 24(3):310-317.
197. Pollack I.F., et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011, 13(3):290-297.
198. Fouladi M., et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 2010, 28(27):4221-4227.
199. Singh A., et al. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR-ErbB2 signaling with lapatinib. Mol. Oncol. 2013, 7(3):497-512.
200. Servidei T., et al. Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models. Int. J. Cancer 2012, 131(5):E791-E803.
201. Meco D., et al. Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma. Transl. Oncol. 2010, 3(5):326-335.
202. Sikkema A.H., et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 2009, 69(14):5987-5995.
203. Gilbertson R.J., et al. Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur. J. Cancer 2006, 42(5):646-649.
204. Dubois S.G., et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 2011, 17(15):5113-5122.
205. Broniscer A., et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J. Clin. Oncol. 2010, 28(31):4762-4768.
206. Broniscer A., et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin. Cancer Res. 2013, 19(11):3050-3058.
207. Faria C.C., et al. AACR 103rd Annual Meeting, Abstract 847: Foretinib, a multi-kinase inhibitor of cMET and PDGFRα, in the treatment of disseminated medulloblastoma. Cancer Res. 2012, 72(8 Suppl. 847).
208. Harris P.S., et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 2012, 12:80.
209. Stewart C.F., et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J. Clin. Oncol. 2004, 22(16):3357-3365.
210. Gilheeney S.W., et al. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr. Blood Cancer 2010, 54(4):591-595.
211. Turner C.D., et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. 2002, 4(2):102-108.
212. Bomgaars L.R., et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J. Clin. Oncol. 2007, 25(29):4622-4627.
213. Aguilera D., et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv. Syst. 2013, 29(4):589-596.
214. Ruggiero A., et al. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. Eur. J. Cancer 2010, 46(16):2943-2949.
215. Kellie S.J., et al. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children. Med. Pediatr. Oncol. 2002, 39(3):168-174.
216. Houghton P.J., et al. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2012, 58(2):200-209.
217. Su J.M., et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin. Cancer Res. 2011, 17(3):589-597.
218. Knipstein J.A., et al. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol. 2012, 14(2):175-183.
219. Milde T., et al. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J. Neurooncol 2012, 110(3):335-348.
220. Hummel T.R., et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr. Blood Cancer 2013, 60(9):1452-1457.
221. Buczkowicz P., et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol. 2013, 23(3):244-253.
222. Miekus K., et al. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Oncol. Rep. 2012, 28(5):1903-1909.
223. Gaspar N., et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol. Cancer Ther. 2010, 9(5):1219-1233. (210).
224. Weigel B.J., et al. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 2007, 13(6):1789-1793.
225. Nageswara Rao A.A., et al. Biologically targeted therapeutics in pediatric brain tumors. Pediatr. Neurol. 2012, 46(4):203-211.
226. Anderson J.L., et al. Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr. Res. 2012, 72(2):112-121.
227. Martin J.W., Squire J.A., Zielenska M. The genetics of osteosarcoma. Sarcoma 2012, 2012:627254.
228. Wang C. Childhood rhabdomyosarcoma: recent advances and prospective views. J. Dent. Res. 2012, 91(4):341-350.
229. Ludwig J.A. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr. Opin. Oncol. 2008, 20(4):412-418.
230. Prieur A., et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 2004, 24(16):7275-7283.
231. Wakahara K., et al. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol. Cancer Res. 2008, 6(12):1937-1945.
232. Wager M.J., Maki R.G. Type 1 insulin growth factor receptor targeted therapies in pediatric cancer. Front. Oncol. 2013, 3:9.
233. Carboni J.M., et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 2009, 8(12):3341-3349.
234. Scotlandi K., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005, 65(9):3868-3876.
235. Tolcher A.W., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 2009, 27(34):5800-5807.
236. Pappo A.S., et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 2011, 29(34):4541-4547.
237. Juergens H., et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 2011, 29(34):4534-4540.
238. Malempati S., et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 2012, 30(3):256-262.
239. Winter G.E., et al. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol. Cancer Ther. 2011, 10(10):1846-1856.
240. Merchant M.S., et al. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J. Natl. Cancer Inst. 2002, 94(22):1673-1679.
241. Bond M., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 2008, 50(2):254-258.
242. Chao J., et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010, 30(2):547-552.
243. Keir S.T., et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2012, 59(3):586-588.
244. Andersson M.K., Aman P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell Int. 2008, 8:1.
245. Fleuren E.D., et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int. J. Cancer 2013, 133(2):427-436.
246. Keshelava N., et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr. Blood Cancer 2009, 53(3):505-508.
247. Kang M.H., et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr. Blood Cancer 2012, 59(1):185-188.
248. Milano G.M., et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesu Children's Hospital experience. Cancer 2006, 106(8):1838-1845.
249. Casey D.A., et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr. Blood Cancer 2009, 53(6):1029-1034.
250. Farhat R., et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution. J. Pediatr. Hematol. Oncol. 2012, 35(5):356-360.
251. Kebudi R., et al. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive Ewing sarcoma family tumors. Pediatr. Hematol. Oncol. 2013, 30(3):170-177.
252. Cassinelli G., et al. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem. Pharmacol. 2012, 84(2):163-171.
253. Fleuren E.D.G., et al. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim. Biophys. Acta 2014, 1845(2):266-276.
254. Gallego Melcon S., Sanchez de Toledo Codina J. Molecular biology of rhabdomyosarcoma. Clin. Transl. Oncol. 2007, 9(7):415-419.
255. Bernasconi M., et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(23):13164-13169.
256. Fredericks W.J., Ayyanathan K., Rauscher F.J. Regulating the neoplastic phenotype using engineered transcriptional repressors. Cancer Lett. 2001, 162(Suppl.):S23-S32.
257. Rodeberg D.A., et al. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. Cancer Immunol. Immunother. 2005, 54(6):526-534.
258. Crouch G.D., Helman L.J. All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res. 1991, 51(18):4882-4887.
259. Bouche M., et al. TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors. Exp. Cell Res. 1993, 208(1):209-217.
260. Herrero Martin D. A. Boro, and B.W. Schafer, Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma. PLoS One 2013, 8(1):e55072.
261. Sharp R., et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat. Med. 2002, 8(11):1276-1280.
262. Taulli R., et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 2006, 66(9):4742-4749.
263. Hou J., et al. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J. Transl. Med. 2011, 9:64.
264. Epstein J.A., et al. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol. Cell. Biol. 1998, 18(7):4118-4130.
265. Taniguchi E., et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008, 27(51):6550-6560.
266. Ehnman M., et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 2013, 73(7):2139-2149.
267. Kalebic T., Tsokos M., Helman L.J. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. 1994, 54(21):5531-5534.
268. Houghton P.J., et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2010, 54(7):921-926.
269. Mayeenuddin L.H., et al. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene 2010, 29(48):6367-6377.
270. Wan X., et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26(13):1932-1940.
271. Marampon F., Ciccarelli C., Zani B.M. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol. Cancer 2006, 5:31.
272. Marampon F., et al. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol. Cancer Ther. 2009, 8(3):543-551.
273. van Gaal J.C., et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J. Clin. Oncol. 2012, 30(3):308-315.
274. van Gaal J.C., et al. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. Eur. J. Cancer 2013, 49(16):3462-3470.
275. Abraham J., et al. Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. Sarcoma 2011, 2011:130484.
276. Smith M.A., et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 51(1):34-41.
277. Lukasiewicz E., et al. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin. J. Physiol. Pharmacol. 2009, 60(3):161-166.
278. Van Winkle P., et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr. Blood Cancer 2005, 44(4):338-347.
279. Klingebiel T., et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr. Blood Cancer 2008, 50(4):739-745.
280. Vassal G., et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J. Clin. Oncol. 2007, 25(4):356-361.
281. Pappo A.S., et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J. Clin. Oncol. 2007, 25(4):362-369.
282. Meazza C., et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med. Oncol. 2009, 26(1):67-72.
283. Hawkins D.S., et al. Children's Oncology Group's 2013 blueprint for research: soft tissue sarcomas. Pediatr. Blood Cancer 2013, 60(6):1001-1008.
284. Takenaka S., et al. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int. J. Oncol. 2010, 36(4):823-831.
285. Allander S.V., et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am. J. Pathol. 2002, 161(5):1587-1595.
286. Nielsen T.O., et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am. J. Pathol. 2003, 163(4):1449-1456.
287. Krskova L., et al. Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma. Cancer Genet. Cytogenet. 2009, 193(1):1-8.
288. Friedrichs N., et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J. Pathol. 2008, 216(4):428-439.
289. Ray-Coquard I., et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008, 13(4):467-473.
290. Joyner D.E., et al. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J. Orthop. Res. 2006, 24(3):474-480.
291. Rheingold S.R., et al. Phase I trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 2007, 25(12):1512-1518.
292. Geryk-Hall M., Hughes D.P. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr. Oncol. Rep. 2009, 11(6):446-453.
293. Messerschmitt P.J., et al. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin. Orthop. Relat. Res. 2008, 466(9):2168-2175.
294. Kolb E.A., et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50(6):1190-1197.
295. Wang Y., et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol. Cancer Ther. 2010, 9(2):410-418.
296. Bagatell R., et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin. Cancer Res. 2011, 17(3):611-619.
297. Lee J.A., et al. Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma?. Cancer Res. Treat. 2012, 44(3):202-209.
298. Somers G.R., et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr. Dev. Pathol. 2005, 8(5):525-532.
299. Yalçin B., et al. C-erbB-2 expression and prognostic significance in osteosarcoma. Pediatr. Blood Cancer 2008, 51(2):222-227.
300. Ebb D., et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J. Clin. Oncol. 2012, 30(20):2545-2551.
301. Kubo T., et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008, 112(10):2119-2129.
302. McGary E.C., et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res. 2002, 8(11):3584-3591.
303. Patane S., et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006, 66(9):4750-4757.
304. Coltella N., et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003, 17(9):1162-1164.
305. Yamaguchi U., et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci. 2009, 100(12):2268-2274.
306. Engin F., et al. Notch signalling contributes to the pathogenesis of human osteosarcomas. Hum. Mol. Genet. 2009, 18(8):1464-1470.
307. Kolb E.A., et al. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr. Blood Cancer 2012, 58(5):815-818.
308. Carol H., et al. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr. Blood Cancer 2014, 61(8):1493-1496.
309. Cai Y., et al. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J. Cell. Biochem. 2014, 115(4):625-631.
310. Chen K., et al. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr. Blood Cancer 2008, 51(3):349-355.
311. Ma Y., et al. Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem. Biophys. Res. Commun. 2013, 431(2):274-279.
312. Carol H., et al. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2010, 55(7):1329-1337.
313. Gorlick R., et al. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2012, 59(3):518-524.
314. Houghton P.J., et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50(4):799-805.
315. Pignochino Y., et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin. Cancer Res. 2013, 19(8):2117-2131.
316. Imai T., et al. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 2003, 22(58):9231-9242.
317. Roh M.S., et al. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 2004, 9(5):583-589.
318. Rao-Bindal K., et al. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr. Cancer Drug Targets 2013, 13(4):411-422.
319. Botter S.M., Neri D., Fuchs B. Recent advances in osteosarcoma. Curr. Opin. Pharmacol. 2014, 16:15-23.
320. Khanna C., et al. Towards a drug development path that targets metastatic progression in osteosarcoma. Clin. Cancer Res. 2014, (Epub ahead of print).
321. Von Hoff D.D., et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 2010, 28(33):4877-4883.
322. Kim E.S., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011, 1(1):44-53.
323. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 1998, 4(5):1079-1086.
324. Gutierrez M.E., Kummar S., Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat. Rev. Clin. Oncol. 2009, 6(5):259-265.
325. Sargent D.J., et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 2005, 23(9):2020-2027.
326. Savas S., Liu G. Genetic variations as cancer prognostic markers: review and update. Hum. Mutat. 2009, 30(10):1369-1377.
327. Gasparini G., Longo R. The paradigm of personalized therapy in oncology. Expert Opin. Ther. Targets 2012, 16(Suppl. 1):S7-S16.
328. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30(7):679-692.
329. Vogelstein B., et al. Cancer genome landscapes. Science 2013, 339(6127):1546-1558.